|
健保碼及健保價 |
|
See related Janumet[捷糖穩] information |
|
|
|
製造商 |
Merck Sharp & Dohme |
|
代理/經銷商 |
Merck Sharp & Dohme |
|
成份 |
Per 50/500 mg tab Sitagliptin 50 mg, metformin HCl 500 mg. Per 50/850 mg tab Sitagliptin 50 mg, metformin HCl 850 mg. Per 50/1000 mg tab Sitagliptin 50 mg, metformin HCl 1,000 mg |
|
適應症 |
As an adjunct to diet & exercise to improve glycemic control in patients with type 2 DM who are not adequately controlled on metformin or sitagliptin alone or in patient already being treated with the combination of sitagliptin & metformin. |
|
用量 |
Individualized dosage not exceeding max daily dose of sitagliptin 100 mg & metformin 2 g. Patients inadequately controlled with diet & exercise alone 50 mg/500 mg bid. Patients inadequately controlled on metformin monotherapy Sitagliptin 50 mg bid + metformin already taken. Patients inadequately controlled on sitagliptin monotherapy 50 mg/500 mg bid. May be titrated up to 50 mg/1000 mg bid. Switching from sitagliptin co-administered with metformin Initiate with dose of sitagliptin & metformin already being taken. Patients inadequately controlled on dual combination therapy with any 2 of the following antihyperglycemic agents: sitagliptin, metformin, sulfonylurea Sitagliptin 50 mg bid + metformin dose based on glycemic control level. Patients currently on or initiating sulfonylurea may require lower doses of sulfonylurea doses to reduce the risk of sulfonylurea-induced hypoglycemia. Gradual dose escalation to reduce GI effects associated with metformin. |
|
過量 |
View Janumet[捷糖穩] overdosage for action to be taken in the event of an overdose. |
|
用法 |
Should be taken with food |
|
美國食品藥物管理局之懷孕等級 |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
禁忌 |
Renal disease or dysfunction, abnormal CrCl which may result from CV collapse, acute MI & septicemia. Acute or chronic metabolic acidosis including diabetic ketoacidosis, with or without coma. Temporarily discontinue treatment in patients undergoing radiologic studies. Type 1 diabetes, diabetic ketoacidosis. |
|
注意事項 |
Regular monitoring of renal function. Unstable or acute CHF at risk of hypoperfusion & hypoxemia. Lactic acidosis. Hypoglycemia. Avoid excessive alcohol intake. Suspend therapy prior to surgical procedure until resumption of oral intake & normal renal function. Impaired hepatic function. Monitor vit B12 level. Pregnancy & lactation. Children < 18 years. Elderly. |
|
不良反應 |
Diarrhea, nausea, vomiting, flatulence, abdominal discomfort, indigestion, asthenia & headache. Hypoglycemia. Hypersensitivity reactions.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
交互作用 |
Metformin: Furosemide, nifedipine, cationic drugs (eg amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, vancomycin). Thiazides & other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, OCs, phenytoin, nicotinic acid, sympathomimetics, Ca antagonists, INH.
View more drug interactions with Janumet[捷糖穩] |
|
儲存 |
View Janumet[捷糖穩] storage conditions for details to ensure optimal shelf-life. |
|
描述 |
View Janumet[捷糖穩] description for details of the chemical structure and excipients (inactive components). |
|
作用 |
View Janumet[捷糖穩] mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Janumet 50/500 mg 膜衣錠 |
|
|
Janumet 50/850 膜衣錠 |
|
|
Janumet 50/1000 膜衣錠 |
|
|
|
Manufacturer: |
Merck Sharp & Dohme |
|
Distributor: |
Merck Sharp & Dohme
|
|
|
|
